Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA

Hermann Einsele, MD, FRCP, University Hospital of Würzburg, Würzburg, Germany, briefly discusses CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA, including agents targeting GPRC5D, CD38 and SLAMF7. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.